HepQuant, LLC

is a biotechnology company founded in 2007 and based in the United States. Their slogan, "Leading the way with innovative technology for assessing liver function in chronic liver disease patients," reflects their mission to revolutionize liver health assessment. The company specializes in developing non-invasive, quantitative tests that measure liver health. One of their key products, the HepQuant DuO Test, provides comprehensive information about liver cell function and portal-systemic shunting, which are crucial attributes associated with clinical outcomes in liver disease. This test offers healthcare providers valuable insights, enabling them to more effectively manage patients with liver diseases. Its results can be used by physicians in conjunction with clinical evaluation and other tests to aid in decision-making processes related to invasive procedures, treatment monitoring, and predicting disease progression and adverse outcomes. This application of advanced technology contributes to more personalized and informed patient care in the field of liver disease treatment. As of now, specific details about last investment and investors are not available. However, the innovative approach and the potential impact of HepQuant's technology in the biotechnology, healthcare, and life sciences sectors make it an entity to watch for modernizing diagnostic and treatment practices in chronic liver diseases.